CARB update
This article was originally published in The Rose Sheet
Executive Summary
California Air Resources Board does not support postponing current plans for collecting consumer product fees since any delay would require manufacturers to pay fees for two fiscal years at about the same time, CARB staff states during Consumer Products Fee Regulation Workgroup teleconference June 19. At the session, CARB staff responded to comments it received following a call for public input on new fees on certain volatile organic-compound-containing consumer products. The Cosmetic, Toiletry and Fragrance Association has urged CARB slow down the regulatory timetable (1"The Rose Sheet" June 2, 2003, p. 5). Workgroup also discussed its staff report and proposed fee regulation, which was released June 6. Second CARB public workshop will be June 24...
You may also be interested in...
CARB Consumer Product Fee Apportionment Details Requested By CTFA
The California Air Resources Board should provide "detailed" information to consumer product manufacturers on the planned apportionment of fees across the industry and the allocation of funds collected to finance activities regulating consumer products, the Cosmetic, Toiletry and Fragrance Association asserts in recent comments
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.